Results 131 to 140 of about 1,121 (157)

Burosumab

Reactions Weekly, 2016
openaire   +1 more source

People also looked at

Frontiers in Endocrinology, 2020
Craig F. Munns, Andrew Biggin, Aaron Schindeler   +2 more
exaly   +2 more sources

Long-term Burosumab Administration Is Safe and Effective in Adults With X-linked Hypophosphatemia.

Journal of Clinical Endocrinology and Metabolism, 2022
Karl Insogna, Erik A Imel, Thomas O Carpenter   +2 more
exaly  

Measuring FGF23 in patients treated with burosumab

Endocrine Abstracts, 2023
Isabelle Piec, Allison Chipchase, Emma Miler, Hari Ramachandran, Emma Webb, William D Fraser   +5 more
openaire   +1 more source

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.

Journal of Clinical Endocrinology and Metabolism, 2022
Gary S Gottesman, Raja Padidela, Noriyuki Namba   +2 more
exaly  

Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia

Journal of Clinical Endocrinology and Metabolism, 2023
Olaf Hiort, Mirko Rehberg, Sabine Heger
exaly  

FGF23 measurement in burosumab-treated patients: an emerging treatment may induce a new analytical interference

Clinical Chemistry and Laboratory Medicine, 2020
Anya Rothenbuhler, Marie-Liesse Piketty, Agnès Linglart   +2 more
exaly  

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.

Journal of Clinical Endocrinology and Metabolism, 2023
Gary S Gottesman, Etienne Sochett, Erik A Imel   +2 more
exaly  

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

Calcified Tissue International, 2019
Karl Insogna, Muhammad K. Javaid, Han-Wook Yoo   +2 more
exaly  

Burosumab for CSHS

Case Medical Research, 2019
openaire   +1 more source